We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 355

FDA proposes amendments to sterility testing for biological products
  • Shook Hardy & Bacon LLP
  • USA
  • June 30 2011

The Food and Drug Administration (FDA) has issued a proposed rule amending the sterility test requirements for biological products, including vaccines and stem-cell treatments


New program to provide accelerated “speed-to-market” for medical device entrepreneurs
  • Shook Hardy & Bacon LLP
  • USA
  • March 1 2012

The nonprofit Memphis Bioworks Foundation and Innova, a pre-seed, seed and early-stage investor, have announced a program designed to help entrepreneurs bring medical device products and companies to market


Proteon lands $15 million in new financing round for kidney disease therapeutic
  • Shook Hardy & Bacon LLP
  • USA
  • August 18 2011

Based in Waltham, Massachusetts, with research facilities in Kansas City, Missouri, Proteon Therapeutics Inc. has reportedly drawn a new $15.2-million financing round


Presidential bioethics panel to examine genome privacy
  • Shook Hardy & Bacon LLP
  • USA
  • April 19 2012

The Presidential Commission for the Study of Bioethical Issues is seeking public comments “on the ethical issues raised by the ready availability of large-scale human genome sequence data, with regard to privacy and data access and the balancing of individual and societal interests.”


Berg, GNS announce joint venture to enhance therapeutic & diagnostic development
  • Shook Hardy & Bacon LLP
  • USA
  • March 10 2011

Massachusetts-based Berg Biosystems, LLC and GNS Healthcare, Inc. have announced a joint venture “to accelerate advancements in critical biomedical research” and reposition “existing drugs for use in new indications with collaborators.”


Campaign seeks to reinforce Hudson Valley as a biotech industry hub
  • Shook Hardy & Bacon LLP
  • USA
  • November 4 2010

Senator Kirsten Gillibrand (D-N.Y.) and business leaders have reportedly unveiled a “NY BioHud Valley” campaign that highlights the state’s Hudson Valley as a “burgeoning epicenter of the biotech industry.”


Financial group analyzes M&A deals in biotech and medical device industries
  • Shook Hardy & Bacon LLP
  • USA
  • June 16 2011

According to an SVP Financial Group report, contrary to conventional wisdom, biotech exits occur faster than device exits and have lower, but solid, multiples on invested capital


Court dismisses French company from suit seeking correction of patent inventorship
  • Shook Hardy & Bacon LLP
  • USA
  • April 7 2011

A federal court in the District of Columbia has dismissed patent-related litigation against a French drug company for lack of personal jurisdiction


Moneytree report shows increased life sciences investments in Q1 2011
  • Shook Hardy & Bacon LLP
  • USA
  • May 19 2011

According to a PricewaterhouseCoopers report on venture capital investments, although fewer deals occurred in the first quarter of 2011 (Q1 2011) as compared to the last quarter of 2010, investment activity increased 5 percent overall


NASDAQ Biotechnology Index surpasses all-time high in 1Q13
  • Shook Hardy & Bacon LLP
  • USA
  • May 16 2013

The NASDAQ Biotechnology Index reportedly rose in the first quarter of 2013 (1Q13) above levels last seen during the 2000 genomics bubble peakthe